ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: It also displays cross-reactivity with other kinases, including Ret, TrkA, FGFR1 and Abl, which may be important in danusertib anticancer activity, since the oncogenic Bcr-Abl tyrosine kinase causes chronic myelogenous leukaemia and BCR-ABL-positive acute lymphocytic leukaemia development [294], being a third-generation Bcr-Abl tyrosine kinase inhibitor with potent anticancer effects [121].